Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14283373 | 0.85 | AOC3 (0.39) | AOC3MAPKAPK2ACVR1BTGFBR1ACACB | |
| SCHEMBL13408184 | 0.83 | RET (0.38) | AOC3MAPKAPK2 | |
| SCHEMBL3608562 | 0.78 | RET (0.45) | — | |
| Trifluoroacetic Acid SCHEMBL3611105 | 0.77 | RET (0.35) | ACACB | |
| SCHEMBL3618292 | 0.75 | MAPKAPK2 (0.53) | MAPKAPK2TGFBR1DYRK1A | |
| SCHEMBL3620527 | 0.74 | PRKCQ (0.39) | MAPKAPK2 | |
| SCHEMBL14283351 | 0.72 | ROCK2 (0.35) | AOC3MAPKAPK2TGFBR1MAPK1DYRK1A | |
| SCHEMBL3611108 | 0.69 | RET (0.35) | MAPK1 | |
| SCHEMBL13408195 | 0.68 | CDK9 (0.38) | MAPKAPK2 | |
| SCHEMBL3614152 | 0.67 | ACVR1B (0.52) | ACVR1BTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | claimed |
| EP-2069333-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | Novartis Ag (CH) | 2009-06-17 | — | — | EP | claimed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | claimed |
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | SLCO1B3, SLCO1B1, SLC10A6 | AOC3 357/4885PTK2 4669/4885MAPKAPK2 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.